Global X - Genomics & Biotechnology ETF

Frequently Asked Questions About GNOM

What does GNOM invest in?

The Global X Genomics & Biotechnology ETF, known by its ticker GNOM, aims to closely track the performance of the Solactive Genomics Index, reflecting both its price appreciation and any generated income. This mirroring occurs before the deduction of the ETF's internal fees and expenses.

What is the expense ratio of GNOM?

Global X - Genomics & Biotechnology ETF (GNOM) charges an expense ratio of 0.50%. This is the annual fee deducted from fund assets to cover management and operations.

How big is GNOM?

Global X - Genomics & Biotechnology ETF (GNOM) manages $109.7M in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure. Funds below ~$50M are at higher risk of liquidation.

Is GNOM actively managed or an index fund?

GNOM's management style is described in the fund's prospectus. See the description on the Summary tab for the published strategy.

When was GNOM launched?

Global X - Genomics & Biotechnology ETF (GNOM) launched in April 2019 and is managed by Global X.

How has GNOM performed?

GNOM's total return (price change plus reinvested distributions) is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.